Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

aclidinium

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

GSK’s Nucala approved by MHRA for uncontrolled COPD

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

- PMLiVE

Almirall and Absci expand AI dermatological drug discovery partnership

The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

- PMLiVE

Merck to expand respiratory disease portfolio with $10bn Verona acquisition

The deal includes a drug approved in the US for chronic obstructive pulmonary disease

- PMLiVE

Almirall hosts Skin Academy to advance skin science and dermatology treatments

The conference will cover actinic keratosis, psoriasis, atopic dermatitis and other skin diseases

- PMLiVE

UK researchers uncover first new asthma and COPD attack treatment in 50 years

The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

- PMLiVE

Eli Lilly/Almirall share positive long-term results for Ebglyss in atopic dermatitis

The inflammatory skin condition occurs in approximately 7.3% of adults in the US

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD

Approximately 1.4 million people in the UK have been diagnosed with the respiratory disease

- PMLiVE

GSK announces positive late-stage results for IL-5 inhibitor Nucala in COPD

The chronic respiratory disease affects more than 300 million people globally

- PMLiVE

Almirall announces NICE recommendation for Ebglyss in atopic dermatitis

The inflammatory skin condition affects about 5.2 million adults and 2.5 million children in the UK

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EMA for uncontrolled COPD in adults

Approximately 220,000 COPD patients in the EU could be eligible for Dupixent treatment

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links